Pfizer
Nasim Massah currently serves as an NGS Scientist in Translational Pathology within Translational Sciences Management at Pfizer since July 2024. Prior to this role, Nasim held various positions at Adaptive Biotechnologies Corp. from January 2017 to March 2024, including Manager of Molecular Research and Senior Research Scientist. Nasim's career began at the Canadian Pharmacogenomics Network for Drug Safety at BC Children's Hospital Research Institute, working as a Research Scientist from September 2011 to December 2016. Additional experience includes multiple roles at The University of British Columbia, where Nasim contributed as a Research Scientist and Research Assistant between 2006 and 2011. Educationally, Nasim completed a Master of Science (MSc) in Population Genetics at The University of British Columbia from 2006 to 2009.
This person is not in any teams
This person is not in any offices
Pfizer
619 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.